Li Huihua, Tai Bee Choo
Biostatistics Unit, Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, 11 Hospital Drive, Singapore 129610, Singapore.
Clin Cancer Res. 2006 Oct 1;12(19):5713-9. doi: 10.1158/1078-0432.CCR-05-2799.
Studies revealing conflicting results on the role of RNASEL polymorphisms Glu265X, Arg462Gln, and Asp541Glu on prostate cancer risk led us to perform a meta-analysis to investigate the association of these polymorphisms and prostate cancer risk.
Relevant studies were selected by searching PubMed from January 1996 to August 2005 using keywords "RNASEL gene AND prostate cancer." For each study, odds ratio (OR) with 95% confidence interval (95% CI) was calculated to estimate the gene effect. Pooled estimates of the OR were computed using the random effects model.
Ten studies were included in the meta-analysis. The overall results suggested no major influence of these variants on prostate cancer risk. However, analysis of the Asp541Glu polymorphism by ethnic populations showed that Asp/Glu (familial cases versus control: OR, 1.38; 95% CI, 1.04-1.82; sporadic cases versus control: OR, 1.26; 95% CI, 1.07-1.48; prostate cancer versus control: OR, 1.29; 95% CI, 1.12-1.48) and Asp/Glu + Glu/Glu (familial cases versus control: OR, 1.37; 95% CI, 1.10-1.70; sporadic cases versus control: OR, 1.24; 95% CI, 1.07-1.44; prostate cancer versus control: OR, 1.27; 95% CI, 1.13-1.44) increased prostate cancer risk in Caucasians, thus suggesting a dominant model for the Glu variant.
Compared with the genotype Asp/Asp, the Glu variant at the Asp541Glu polymorphism increases prostate cancer risk by <2-fold in Caucasians, regardless of family history of the disease. This suggests that genuine genetic effects of this polymorphism may account for only a part of prostate cancer in the Caucasian population.
关于RNASEL基因多态性Glu265X、Arg462Gln和Asp541Glu在前列腺癌风险中作用的研究结果相互矛盾，这促使我们进行一项荟萃分析，以研究这些多态性与前列腺癌风险之间的关联。
通过使用关键词“RNASEL基因AND前列腺癌”检索1996年1月至2005年8月的PubMed来选择相关研究。对于每项研究，计算比值比（OR）及95%置信区间（95%CI）以估计基因效应。使用随机效应模型计算OR的合并估计值。
荟萃分析纳入了10项研究。总体结果表明这些变异对前列腺癌风险没有重大影响。然而，按种族人群对Asp541Glu多态性进行分析显示，在白种人中，Asp/Glu（家族性病例与对照相比：OR，1.38；95%CI，1.04 - 1.82；散发性病例与对照相比：OR，1.26；95%CI，1.07 - 1.48；前列腺癌与对照相比：OR，1.29；95%CI，1.12 - 1.48）和Asp/Glu + Glu/Glu（家族性病例与对照相比：OR，1.37；95%CI，1.10 - 1.70；散发性病例与对照相比：OR，1.24；95%CI，1.07 - 1.44；前列腺癌与对照相比：OR，1.27；95%CI，1.13 - 1.44）会增加前列腺癌风险，这表明Glu变异存在显性模式。
与Asp/Asp基因型相比，无论疾病家族史如何，Asp541Glu多态性中的Glu变异在白种人中使前列腺癌风险增加不到2倍。这表明该多态性真正的遗传效应可能仅占白种人群前列腺癌的一部分。
